ASCENDIS PHARMA A/S

ASNDNASDAQ

🏆 #478 by market capEarnings Nov 6 · PostUS Equity

$502.66▲ $10.10 (+2.01%)

Simulated price

1h—

24h▲ 2.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$18.41B

Mid Cap

📈Revenue Growth (YoY)

+134.8%

High Growth

📊Gross Margin

89.0%

High

💵FCF Margin

—

⚖️P/S Ratio

16.0x

Expensive

Otter Score

Weak

No chart data available for ASND.

Trading Snapshot

Day Range: $500.06 – $510.34
52-Week Range: —
Volume: $2.81B
Avg Volume: $1.91B
Shares Outstanding: 66.2M
Next Earnings: Sep 23, 2026

Fundamentals Snapshot

Annual Revenue: $692M
Last Q Revenue: $251M
P/E Ratio: 27.9
P/S Ratio: 16.0x
EPS (TTM): —
Dividend Yield: —

Why Investors Own ASND

✓High-growth profile — revenue up +34.0% YoY with expanding US Equity exposure.
✓Healthy economics — 74% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$692M▲ +36.1% YoY

Gross Margin (TTM)

73.9%▲ +1.5% YoY

Operating Income (TTM)

$131M▲ +36.1% YoY

Free Cash Flow (TTM)

$104M▲ +36.1% YoY

About ASCENDIS PHARMA A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

🦦